Mayo Vaccine Research Group, Department of Medicine, Mayo Clinic College of Medicine, Mayo Foundation, Rochester, Minnesota, United States of America.
PLoS Pathog. 2011 Dec;7(12):e1002344. doi: 10.1371/journal.ppat.1002344. Epub 2011 Dec 29.
As is apparent in many fields of science and medicine, the new biology, and particularly new high-throughput genetic sequencing and transcriptomic and epigenetic technologies, are radically altering our understanding and views of science. In this article, we make the case that while mostly ignored thus far in the vaccine field, these changes will revolutionize vaccinology from development to manufacture to administration. Such advances will address a current major barrier in vaccinology-that of empiric vaccine discovery and development, and the subsequent low yield of viable vaccine candidates, particularly for hyper-variable viruses. While our laboratory's data and thinking (and hence also for this paper) has been directed toward viruses and viral vaccines, generalization to other pathogens and disease entities (i.e., anti-cancer vaccines) may be appropriate.
在许多科学和医学领域中，新生物学，尤其是新的高通量基因测序以及转录组和表观遗传技术，正在从根本上改变我们对科学的理解和认识。在本文中，我们认为，尽管这些变化在疫苗领域迄今为止大多被忽视，但它们将从研发到生产再到管理彻底改变疫苗学。这些进展将解决疫苗学中的一个当前主要障碍，即经验性疫苗发现和开发，以及随后可行疫苗候选物的低产量，尤其是对于高变异性病毒。虽然我们实验室的数据和思路（因此本文也是如此）一直针对病毒和病毒疫苗，但将其推广到其他病原体和疾病实体（即抗癌疫苗）可能是合适的。
